This guidance sets out the full process that follows the death of a child who is normally resident in England. It builds on existing statutory requirements and clarifies how individual professionals and organisations across all sectors should contribute to child death reviews.
A report by the Royal College of Paediatrics and Child Health (RCPCH) compares health outcomes of children and young people in England compared with other wealthy European and western countries. It uses historical data and modelling techniques to project likely outcomes in 2030, and recommends that NHS England develops a strategy for children and young people’s health.
NHS hospitals stand to save £150m a year as the NHS’s most costly drug becomes cheaper.
Adalimumab is the single medicine on which hospitals spend the most, at a cost of more than £400 million a year. As the patent has now expired, most patients can now expect to be treated with a much cheaper ‘biosimilar’.
At least 80% of existing patients should be switched to the best value equivalent within 12 months, NHS England has told CCGs and trusts.